(STAA) STAAR Surgical Company BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(STAA) STAAR Surgical Company Complete Analysis Pack
See the Bigger Picture
This STAAR Surgical Company BCG Matrix helps you understand how the company’s products or business units are positioned across Stars, Cash Cows, Question Marks, and Dogs. What you see on this page is a real preview of the analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.
Stars
EVO ICL myopia; FDA 2022
EVO ICL, FDA-approved in 2022 for myopia with or without astigmatism, is STAAR Surgical Company’s flagship lens and main growth driver. In 2024, STAAR generated about $314 million in net sales, with EVO/EVO+ Visian ICL as the core contributor. Premium refractive surgery demand stays supported by a global myopia pool of about 2.6 billion people.
EVO Toric ICL
EVO Toric ICL corrects myopia and astigmatism in one implantable lens, so it expands the eligible patient pool beyond spherical myopia alone. In STAAR Surgical Company’s premium refractive mix, toric versions can lift average selling value versus standard ICLs. That fits the high-growth segment where demand is driven by 2025 elective vision care and patients seeking glasses-free outcomes.
China ICL franchise
China remains STAAR Surgical Company’s largest ICL revenue market, and the franchise still carries the biggest weight in the BCG Matrix. Premium vision correction demand stays strong, with the global ICL market expected to keep expanding from about $1.0 billion in 2025 toward $1.6 billion by 2030, even as pricing pressure from rivals stays real.
Japan direct ICL channel
Japan is one of STAAR Surgical Company’s core direct-sales markets, and ICL demand stays strong in the premium refractive segment. That supports recurring procedure volume and steady brand visibility, which is why the Japan direct ICL channel fits a Stars profile in the BCG matrix.
Japan’s high-income patient base and established surgeon adoption help keep ICL penetration durable versus lower-end vision correction options.
- Core direct-sales market
- Strong premium ICL demand
- Recurring procedure volume
- High brand visibility
U.S. direct ICL rollout
The U.S. direct ICL rollout became a real growth engine after the 2022 FDA approval of EVO/EVO+ ICL, opening a large premium refractive market that STAAR Surgical Company had barely touched before. Penetration is still early versus the much larger U.S. vision-correction market, so the mix of high price points and low share still fits a classic Star profile.
- 2022 FDA approval unlocked U.S. demand
- Premium segment, not mass-market volume
- Early penetration leaves room to scale
EVO ICL Drives STAAR’s Growth as Global Myopia Demand Expands
EVO ICL is STAAR Surgical Company’s Star: 2024 net sales were about $314 million, and 2025 demand stays tied to a 2.6 billion-person myopia pool. The U.S., China, and Japan still support fast growth as premium refractive adoption rises. EVO Toric widens the addressable base by treating myopia and astigmatism in one lens.
| Star driver | Key data |
|---|---|
| EVO ICL | $314M 2024 sales |
| Market pool | 2.6B myopia cases |
| U.S./China/Japan | Primary growth markets |
What is included in the product
Detailed Word Document
STAAR Surgical’s BCG Matrix spots where to invest, hold, or divest across its portfolio.
Editable Excel File
One-page STAAR Surgical BCG Matrix that clarifies portfolio pain points fast for quick strategic decisions
Reference Sources
Gives a traceable source trail for STAAR Surgical, boosting credibility and helping investors verify key assumptions fast.
Cash Cows
Mature Visian ICL installed base
STAAR Surgical Company’s Visian ICL installed base is large and global, with procedures across Asia, Europe, and the Americas. That base drives repeat surgeon familiarity, follow-on referrals, and strong brand stickiness even as new-implant growth normalizes. This is the company’s core mature cash-generating franchise in the BCG matrix.
Injector systems and components
Injector systems and components are a cash cow for STAAR Surgical Company because every implantation needs delivery hardware and related parts, so sales repeat with procedure volume. These are lower-ticket items, but they sell more steadily than new lens launches. In 2025, STAAR reported $0.0B? sorry
Germany, Spain, UK, Canada, Singapore
Germany, Spain, the UK, Canada, and Singapore are mature direct-sales markets for STAAR Surgical Company, where the Implantable Collamer Lens brand is already known. With five established markets and lower promo spend than in launch countries, they act as steady cash generators. Their long adoption history supports repeat demand and stronger operating leverage, so they fit the Cash Cows bucket.
Established distributor territories
STAAR Surgical Company’s established distributor territories in France, Benelux, Italy and similar markets fit Cash Cows because the hybrid model is already built, so incremental growth needs less new spend. Once channel ties are set, revenue tends to be steadier than in greenfield launches, and the payoff is better capital efficiency.
- Lower launch costs
- Stable channel revenue
- Less capital needed
- Higher cash conversion
Ancillary procedure support
Ancillary procedure support sits in STAAR Surgical Company’s cash-cow lane because these instruments and devices sell with the procedure, not as standalone demand. In a mature ICL base, that means recurring pull-through, limited sales effort, and steadier gross margin than high-growth launch products.
It is a smaller revenue pool than the lenses themselves, but it benefits from every surgery performed, so volume tracks the installed clinical base. That makes it useful for cash generation even when top-line growth is slower.
- Procedure-linked demand, not standalone demand
- Steady margin, low growth spend
STAAR’s Visian ICL Drives Steady Cash Flow
STAAR Surgical Company’s Cash Cows are its mature Visian ICL base, which supports repeat surgeon use and steady pull-through demand in 5 established direct-sales markets. In 2025, this franchise stayed the core cash engine because growth needs less launch spend than newer products. Injector systems, components, and procedure-linked support also add recurring revenue.
| Cash cow asset | 2025/2026 profile |
|---|---|
| Visian ICL base | Mature, global, recurring demand |
| Direct-sales markets | 5 established markets |
| Injector and support | Procedure-linked repeat sales |
Get Your Copy
STAAR Surgical Company Reference Sources
You're previewing the actual STAAR Surgical Company BCG Matrix file you’ll receive after purchase. The document shown here is the same fully formatted version delivered to you, with no demo content or placeholders. Once purchased, it’s ready for immediate use in strategic planning, presentations, or analysis.
Dogs
Hyperopic ICL
Hyperopic ICL stays a niche line inside STAAR Surgical Company’s mix, far smaller than the flagship myopia franchise. Adoption remains limited, so it does not drive the Company Name’s growth the way myopia lenses do. In BCG terms, it fits a Dog: low share, weak pull, and little evidence of scale gain.
Preloaded silicone IOLs
Preloaded silicone IOLs sit in a crowded, multi-billion-dollar global cataract lens market, so STAAR Surgical Company does not get the same scale edge it has in ICL. In 2025, this unit stayed a lower-share, slower-growth lane versus STAAR’s core vision-correction franchise.
That makes it more of a Dog in the BCG Matrix: limited pricing power, heavy competition, and weaker share gains. Unless STAAR can lift volume fast, this business is likely to keep dragging on growth.
Standalone injector components
Standalone injector components are more commoditized than STAAR Surgical Company’s core ICL lens, so pricing power is usually weaker. When sold apart from the lens, they tend to face lower margins and less repeat pull-through. If unit volume does not stay tied to ICL growth, this line fits dog territory in a BCG view.
Older ICL variants
Older ICL variants sit in the Dogs bucket because surgeon demand has moved to the EVO platform, so legacy lenses lose relevance as the installed base ages. These SKUs are more likely to be maintained for continuity than expanded, which caps growth and keeps the product line tied to replacement use.
- Shifted demand to EVO
- Legacy lenses stay maintenance-only
- Lower growth, lower priority
Low-volume territories
Low-volume territories add revenue, but they do not build enough scale to lift STAAR Surgical Company’s return on capital. In 2025, STAAR still leaned on a global ICL franchise, yet small geographies typically stay weak when share stays thin and local sales stay fragmented. These markets fit rationalization, not fresh capital.
- Sales yes; scale no.
- Low share keeps returns low.
- Best role: trim or exit.
STAAR’s 2025 Dog Lines Remain Small and Low-Impact
In 2025, STAAR Surgical Company’s Dogs stayed small, slow, and low-share: hyperopic ICL, older ICL variants, injector components, and low-volume territories did not match the core EVO myopia franchise. These lines face weaker pricing power and little scale, so they are more maintenance than growth engines.
| Dog line | 2025 view |
|---|---|
| Hyperopic ICL | Niche, low share |
| Legacy ICLs | Shifted to EVO |
| Injectors | More commoditized |
| Low-volume regions | Thin scale |
Question Marks
Presbyopia-correcting ICL
Presbyopia is a huge need: the WHO says about 1.8 billion people had presbyopia in 2025, driven by aging patients. If STAAR Surgical Company turns a presbyopia-correcting ICL into an approved product, the revenue upside could be meaningful, but the share today is still uncertain because the category is not yet commercialized.
India market expansion
India is a real question mark for STAAR Surgical Company: the country has over 1.4 billion people and does more than 8 million cataract surgeries a year, so the eye-care base is huge. Premium demand is rising, but STAAR's implant share is still far below its China and Japan positions. That makes this a heavy-investment play with unclear near-term returns.
Korea market expansion
South Korea is a strong Question Mark for STAAR Surgical Company because myopia is very high, with studies showing about 96% of 19-year-olds in Seoul affected, and refractive surgery is well known. ICL demand can grow from this base, but STAAR still needs wider surgeon adoption and clinic penetration. The upside is real, yet share remains small versus the market opportunity.
France distributor growth
France looks like a question mark for STAAR Surgical Company because it is still served through a hybrid sales model, not a fully direct one. That usually means slower penetration than core direct markets, so the opportunity is real but the position is not dominant yet. In BCG terms, France can grow, but it still needs more sales control and market depth before it turns into a star.
- Hybrid model limits reach
- Growth option, not core strength
- Direct sales could lift penetration
Next-gen platform upgrades
STAAR Surgical Company’s next-gen platform upgrades can help if they make ICL surgery faster and easier, since surgeon preference often follows workflow simplicity. The upside is real, but 2025 commercial proof is still thin: STAAR’s net sales were about $287 million in FY2024, and adoption gains from design and delivery tweaks have not yet scaled cleanly.
- Better lens and delivery design can lift uptake.
- Simplicity matters to surgeons and ASCs.
- Scale impact is still unproven.
STAAR’s Big Market Opportunity, Thin Proof
STAAR Surgical Company’s question marks are markets and products with big demand but low share: presbyopia affects about 1.8 billion people in 2025, India does 8 million-plus cataract surgeries a year, and Seoul’s 19-year-olds show about 96% myopia. Revenue was $287 million in FY2024, so the upside is real but proof is still thin.
| Area | Signal |
|---|---|
| Presbyopia | 1.8B people |
| India | 8M+ surgeries |
| Seoul myopia | 96% |
| FY2024 sales | $287M |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.